Shire PLC (LON:SHP) has earned a consensus rating of “Buy” from the twenty analysts that are presently covering the firm. One research analyst has rated the stock with a sell recommendation, seventeen have given a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is GBX 5,970.29 ($73.95).

Several research firms recently weighed in on SHP. JPMorgan Chase & Co. reissued an “overweight” rating and set a GBX 6,300 ($78.04) price objective on shares of Shire PLC in a research report on Tuesday, August 23rd. Shore Capital reissued a “buy” rating on shares of Shire PLC in a research report on Tuesday, August 30th. Deutsche Bank AG reissued a “buy” rating and set a GBX 6,000 ($74.32) price objective on shares of Shire PLC in a research report on Monday, September 19th. Jefferies Group reissued a “buy” rating and set a GBX 6,600 ($81.75) price objective on shares of Shire PLC in a research report on Monday, October 31st. Finally, Goldman Sachs Group Inc. reissued a “buy” rating and set a GBX 6,300 ($78.04) price objective on shares of Shire PLC in a research report on Wednesday, October 12th.

Shire PLC (LON:SHP) opened at 4997.50 on Wednesday. Shire PLC has a 52-week low of GBX 2,707.19 and a 52-week high of GBX 5,562.83. The company’s 50-day moving average price is GBX 4,973.54 and its 200-day moving average price is GBX 4,691.24. The firm’s market cap is GBX 44.99 billion.

In other news, insider Dominic Blakemore bought 133 shares of the stock in a transaction dated Friday, September 30th. The stock was bought at an average cost of GBX 5,010 ($62.06) per share, with a total value of £6,663.30 ($8,253.81).

Shire PLC Company Profile

Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.

Receive News & Stock Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related stocks with our FREE daily email newsletter.